Viatris is undergoing a strategic transformation, shedding assets and reducing debt from $18.2B to $13.6B, yet equity erosion and a D/E ratio of 0.96 indicate leverage is not improving.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth turned positive at 4.9% in 2026Q2, yet gross margin volatility (30.6% to 41.1% over ten quarters) and a near-zero operating margin of 0.2% indicate persistent cost and pricing pressures.
Viatris reported improved sales and net income, with sales rising to US$3,509.7 million from US$3,243.2 million and net income turning positive to US$176.4 million.
Viatris has a diverse portfolio of over 1,400 molecules across major therapeutic areas, including best-in-class branded products and generics.
The merger of Mylan and Upjohn has positioned Viatris to bridge the gap between generics and branded drugs, creating a unique global healthcare company.
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | $0.71+11.5% vs $0.64 | $3.7B-1.0% vs $3.8B |
Q3 2026 Aug 6, 2026 | $0.69+14.8% vs $0.60 | $3.8B+2.2% vs $3.7B |
Q2 2026 May 7, 2026 | $0.59+17.5% vs $0.50 | $3.5B+4.8% vs $3.4B |
Q1 2026 Feb 26, 2026 | $0.57+7.1% vs $0.53 | $3.7B+4.8% vs $3.5B |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The headline numbers for Viatris (VTRS) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Viatris Inc. (VTRS) Q3 2026 Earnings Call Transcript
VTRS beats Q3 earnings estimates on stronger margins and raises 2026 earnings guidance, despite revenue miss and persistent supply constraints.
Benchmark VTRS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Viatris Inc. (VTRS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $19.91 | $23.19B | -37.62 | -2.98% | -4.13% | -4.24% | 2.41% | |
| $42.61 | $50.41B | 99.63 | 4.31% | 2.94% | 6.35% | — | |
| $20.14 | $6.43B | 45.82 | 8.05% | 4.62% | 82.23% | — | |
| $15.85 | $2.19B | -1.25 | -2.75% | -43.27% | -68.13% | 7.26% | |
| $29.39 | $167.51B | 41.91 | -1.65% | 6.34% | 4.58% | 5.85% | |
| $146.73 | $362.4B | 148.23 | 1.18% | 3.64% | 5.29% | 2.22% |
Viatris Inc. (VTRS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Viatris Inc. (VTRS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jul 1, 2026·SEC
Jun 18, 2026·SEC
Get notified when VTRS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Viatris Inc. (VTRS) stock FAQ — growth, dividends, profitability & financials explained
Viatris Inc. (VTRS) reported $14.73B in revenue over the trailing twelve months. Revenue was $14.30B in fiscal year 2025. That is 940% more than the $1.37B of fiscal year 2003.
Viatris Inc. (VTRS) grew revenue by 4.3% over the trailing twelve months, compared with the twelve months before.
No. Viatris Inc. (VTRS) reported a net loss of $607.8M over the trailing twelve months.
Yes. Viatris Inc. (VTRS) pays a dividend that yields 2.41% at the current price, a moderate yield.
Viatris Inc. (VTRS) had a return on equity (ROE) of -4.2% over the trailing twelve months. A negative ROE means the company lost money over the period.
Viatris Inc. (VTRS) generated $2.04B in free cash flow over the trailing twelve months.
